Tumour biological features of BRCA1-induced breast and ovarian cancer

European Journal of Cancer Part A

Volumn 33, Issue 3, 1997, Pages 362-371

  Jóhannsson, Ó T ^a   Idvall, I ^a   Anderson, C ^a   Borg, Å ^a   Barkardottir R B ^b   Egilsson, V ^b   Olsson, H ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

BRCA1; breast carcinoma; c erbB 2; ER; hereditary neoplasm; histopathology; immunohistochemistry; ovarian carcinoma; TP53; tumour infiltration

Indexed keywords

ARTICLE; BREAST CANCER; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA CONTENT; FAMILIAL CANCER; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL;

EID: 0031105976     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)89007-7     Document Type: Article

References (44)

1. Shattuck-Eidens D, McClure M, Simard J, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA. 273:1995;535-541.
2. Claus EB, Risch N, Thompson WD, Carter D. Relationship between breast histopathology and family history of breast cancer. Cancer. 71:1993;147-153.
3. Goldgar DE, Fields P, Lewis CM, et al. A large kindred with 17q-linked breast and ovarian cancer: genetic, phenotypic, and genealogical analysis. J Natl Cancer Inst. 86:1994;200-209.
4. Marcus J, Watson P, Page DL, et al. Hereditary breast cancer. Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer. 77:1996;697-709.
5. Eisinger F, Stoppa-Lyonnet D, Longy M, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res. 56:1996;471-474.
6. Easton DF, Narod SA, Ford D, Steel M. The genetic epidemiology of BRCA1. Breast cancer linkage consortium [letter]. Lancet. 344:1994;761.
7. Bewtra C, Watson P, Conway T, Read-Hippee C, Lynch HT. Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol. 11:1992;180-187.
8. Piver MS, Baker TR, Jishi MF, et al. Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer. 71:(Suppl 2):1993;582-588.
9. Johansson OT, Ostermeyer EA, Håkansson S, et al. Founding BRCA1 mutations in hereditary breast and ovarian cancer in Southern Sweden. Am J Hum Genet. 58:1996;441-450.
10. Arason A, Barkardottir RB, Egilsson V. Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic cancer. Am J Hum Genet. 52:1993;711-771.
11. Azzopardi JG, Chepick OF, Hartman WH, Jafarey NA, Llombart-Bosch A, Ozzelo L. Histological typing of breast tumours. International Histological Classification of Tumours. 1981;WHO, Geneva. No. 2.
12. Elston CW. Grading of invasive carcinoma of the breast. Page D, Anderson TJ. 1st edn. Diagnostic Histopathology of the Breast. 1987;300-311 Churchill Livingstone, New York.
13. Lash RH, Bauer TW, Hermann RE, Esselstyn CB. Partial mastectomy: pathologic findings and prognosis. Hum Pathol. 17:1986;813-822.
14. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 39:1991;741-748.
15. Heubner A, Beck T, Grill H, Pollow K. Comparison of immunocytochemical estrogen receptor assay, estrogen receptor enzyme immunoassay, and radioligand-labeled estrogen receptor assay in human breast cancer and uterine tissue. Cancer Res. 46:(Suppl 8):1986;4291s-4295s.
16. Hedley D, Friedlander M, Taylor I, Rugg C, Musgrove E. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem. 31:1983;1333-1335.
17. Schutte B, Reynders MM, Bosman FT, Blijham GH. Flow cytometric determination of DNA ploidy level in nuclei isolated from paraffin-embedded tissue. Cytometry. 6:1985;26-30.
18. Baldetorp B, Dalberg M, Holst U, Lindgren G. Statistical evaluation of cell kinetic data from DNA flow cytometry (FCM) by the EM algorithm. Cytometry. 10:1989;695-705.
19. Hiddeman W, Schuman J, Andreeff M, et al. Convention on nomenclature for DNA cytometry. Cytometry. 5:1984;445-446.
20. Baisch H, Gohde W, Linden WA. Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiat Environ Biophys. 12:1975;31-39.
21. Friedman LS, Ostermeyer EA, Szabo CI, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nature Genet. 8:1994;399-404.
22. Lathrop GM, Lalouel JM, Julier C, Ott J. Strategies for multilocus linkage analysis in humans. Proc Natl Acad Sci USA. 81:1984;3443-3446.
23. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 52:1993;678-701.
24. Baptista J, Pike M. Exact confidence limits for the odds-ratios in a two by two table. Appl Stat. 26:1977;214-220.
25. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nature Genet. 9:1995;444-450.
26. Chen Y, Chen CF, Riley DJ, et al. Aberrant subcellular localisation of BRCA1 in breast cancer. Science. 270:1995;789-791.
27. Futreal PA, Liu Q, Shattuck-Eidens O, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 266:1994;120-122.
28. Merjaver SD, Pham TM, Caduff RF, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet. 9:1995;439-443.
29. Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer. 40:1977;1365-1385.
30. Linell F, Ljungberg O, Andersson I. Breast carcinoma. Aspects of early stages, progression and related problems. Acta Pathol Microbiol Scand. (Suppl 272):1980;1s-233s.
31. Balch CM, Riley LB, Bae YJ, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg. 125:1990;200-205.
32. O'Sullivan C, Lewis CE. Tumor-associated leucocytes: friends or foes in breast carcinoma. J Pathol. 172:1994;229-235.
33. Naukkarinen Syrjanen KJ. Quantitative immunohistochemical analysis of mononuclear infiltrates in breast carcinomas - correlation with tumour differentiation. J Pathol. 160:1990;217-222.
34. Zuk JA, Walker RA. Immunohistochemical analysis of HLA antigens and mononuclear infiltrates of benign and malignant breast cancer. J Pathol. 152:1987;275-285.
35. Bilik R, Mor C, Hazaz B, Moroz C. Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer. Cancer Immunol Immunother. 28:1989;143-147.
36. Clark GM. Prognostic and predictive factors. Harris JR, Lippman ME, Morrow M, Hellman S. 1st edn. Diseases of the Breast. 1996;461-485 Lippincott-Raven, Philadelphia.
37. Poller DN, Hutchings CE, Galea M, et al. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer. 66:1992;583-588.
38. Trock BJ. Molecular epidemiology. Harris JR, Lippman ME, Morrow M, Hellman S. 1st edn. Diseases of the Breast. 1996;213-220 Lippincott-Raven, Philadelphia.
39. Osborne CK, Clark GM, Ravdin PM. Adjuvant systemic therapy of primary breast cancer. Harris JR, Lippman ME, Morrow M, Hellman S. 1st edn. Diseases of the Breast. 1996;548-578 Lippincot-Raven, Philadelphia.
40. Olsson H, Ranstam J, Baldetorp B, et al. Proliferation and DNA ploidy in malignant breast tumours in relation to early contraceptive use and early abortions. Cancer. 67:1991;1285-1290.
41. Olsson H, Borg Å, Fernö M, Ranstam J, Sigurdsson H. Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumours in relation to reproductive factors and exposure to exogenous hormones. J Natl Cancer Inst. 83:1991;1483-1487.
42. Thor AD, Moore DH II, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst. 84:1992;845-855.
43. Koonin EV, Altschul SF, Bork P. BRCA1 protein products: functional motifs. Nat Genet. 13:1996;266-267.
44. Porter DE, Cohen BB, Wallace MR, et al. Breast cancer incidence penetrance and survival in probable carriers of BRCA1 mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg. 81:1994;1512-1515.